Back to School: How biopharma can reboot drug development. Access exclusive analysis here

An insulin-conjugated dual SLC2A1/SLC2A4 inhibitor for diabetes

DISEASE CATEGORY: Endocrine/metabolic

INDICATION: Diabetes

A team led by Zenomics Inc. scientific co-founder Zhen Gu identified an insulin-conjugated

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE